Policy in focus: Trump’s Most Favoured Nations drug pricing ...

Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.

MAPs, EAPs, and patient access: Suzanne Aitken on the challe...

Suzanne Aitken, SVP of managed access at Clinigen, discussing the role of managed access programmes in the current pharmaceutical landscape.

Why Datavant bought Aetion, and what comes next, with Arnaub...

The changing landscape of drug clinical assessment: Tommy Br...

In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.

EAPs: Market access outside of the US and Western Europe

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals about early access programmes.

The value of a partner, globally and locally

A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face